AR106956A1 - Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación - Google Patents

Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación

Info

Publication number
AR106956A1
AR106956A1 ARP160103793A ARP160103793A AR106956A1 AR 106956 A1 AR106956 A1 AR 106956A1 AR P160103793 A ARP160103793 A AR P160103793A AR P160103793 A ARP160103793 A AR P160103793A AR 106956 A1 AR106956 A1 AR 106956A1
Authority
AR
Argentina
Prior art keywords
mutations
open reading
viruses
orf
phenotypes
Prior art date
Application number
ARP160103793A
Other languages
English (en)
Spanish (es)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of AR106956A1 publication Critical patent/AR106956A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP160103793A 2015-12-11 2016-12-12 Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación AR106956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266199P 2015-12-11 2015-12-11

Publications (1)

Publication Number Publication Date
AR106956A1 true AR106956A1 (es) 2018-03-07

Family

ID=57714677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103793A AR106956A1 (es) 2015-12-11 2016-12-12 Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación

Country Status (9)

Country Link
US (2) US10655109B2 (enExample)
EP (1) EP3386539A1 (enExample)
JP (2) JP7079197B2 (enExample)
KR (2) KR102854980B1 (enExample)
CN (1) CN109310752B (enExample)
AR (1) AR106956A1 (enExample)
AU (1) AU2016366771B2 (enExample)
CA (1) CA3007408A1 (enExample)
WO (1) WO2017100759A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630173A1 (en) * 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
US20230279362A1 (en) * 2020-06-05 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Live attenuated respiratory syncytial virus
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2002044334A2 (en) * 2000-11-28 2002-06-06 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
WO2015041924A2 (en) * 2013-09-18 2015-03-26 Medimmune, Llc Recombinant respiratory syncytial virus (rsv) and caccines
US10947512B2 (en) 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods

Also Published As

Publication number Publication date
RU2018125246A3 (enExample) 2020-05-25
CN109310752B (zh) 2022-12-16
BR112018011674A2 (pt) 2018-12-04
US20190040365A1 (en) 2019-02-07
US11332721B2 (en) 2022-05-17
KR102854980B1 (ko) 2025-09-03
JP2018536428A (ja) 2018-12-13
JP7079197B2 (ja) 2022-06-01
US20200283740A1 (en) 2020-09-10
CN109310752A (zh) 2019-02-05
JP7357709B2 (ja) 2023-10-06
RU2018125246A (ru) 2020-01-15
KR20180085803A (ko) 2018-07-27
KR20250134719A (ko) 2025-09-11
CA3007408A1 (en) 2017-06-15
WO2017100759A1 (en) 2017-06-15
AU2016366771B2 (en) 2022-04-07
EP3386539A1 (en) 2018-10-17
AU2016366771A1 (en) 2018-07-12
JP2022088376A (ja) 2022-06-14
US10655109B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CO2018006706A2 (es) Virus mutados, método de preparación y uso de los mismos
MX2018014573A (es) Vacuna contra el virus del zika.
CO2018001534A2 (es) Una composicion de vacuna arboviral
EP4218807A3 (en) Zika virus vaccine
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX2016011055A (es) Nuevo polisacarido y usos del mismo.
MX382425B (es) Imitadores de mir-29 y usos de los mismos
CO2018003451A2 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
MX2019005136A (es) Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
MX387421B (es) Producción de virus en huevos aviares.
ECSP11011033A (es) Virus sincitial respiratorio vivo atenuado
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
DOP2018000209A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
MX2018006373A (es) Produccion de virus en cultivos celulares.
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
CL2017001722A1 (es) Un método de activación de bacterias ácido lácticas
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
BR112017004452A2 (pt) vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
AR099680A1 (es) Muteínas mejoradas de factor viii de coagulación
CL2018000076A1 (es) Mejora del metabolismo de las microalgas de xilosa.